Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nanoemulsion

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44365   clinical trials with a EudraCT protocol, of which   7389   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Nanoemulsion. Displaying page 1 of 1.
    EudraCT Number: 2015-004111-20 Sponsor Protocol Number: Q291dnro62/2015 Start Date*: 2016-01-12
    Sponsor Name:Janne Räsänen
    Full Title: Photodynamic therapy for Lentigo maligna with 5-aminolaevulinic acid nanoemulsion (BF-200 ALA)
    Medical condition: Lentigo maligna
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000624-37 Sponsor Protocol Number: CLOBOF3-17IA03 Start Date*: 2022-10-05
    Sponsor Name:Laboratorios Salvat, S.A.
    Full Title: A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% i...
    Medical condition: Inflammation and pain associated with ocular surgery.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015943 Eye inflammation PT
    20.0 10015919 - Eye disorders 10015958 Eye pain PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000314-20 Sponsor Protocol Number: ALA-AK-CT001 Start Date*: 2006-09-26
    Sponsor Name:Biofrontera Bioscience GmbH
    Full Title: A randomized placebo-controlled clinical trial of topical photodynamic therapy with a nanoemulsion formulation of 5-aminolevulinic acid for the treatment of actinic keratosis
    Medical condition: actinic keratosis (AK)
    Disease: Version SOC Term Classification Code Term Level
    10000614
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006854-24 Sponsor Protocol Number: ALA-AK-CT002 Start Date*: 2008-04-17
    Sponsor Name:Biofrontera Bioscience GmbH
    Full Title: A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of a nanoemulsion gel formulation BF-200 ALA, in comparison with Metvix® and placebo, for the treatme...
    Medical condition: Actinic keratosis (AK)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000614 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003371-39 Sponsor Protocol Number: ALA-AK-CT003 Start Date*: 2007-12-04
    Sponsor Name:Biofrontera Bioscience GmbH
    Full Title: A randomized, double-blind, phase III multicenter study evaluating the safety and efficacy of BF-200 ALA versus placebo in the treatment of actinic keratosis when using PDT
    Medical condition: actinic keratosis (AK)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000614 Actinic keratosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003241-42 Sponsor Protocol Number: ALA-BCC-CT008 Start Date*: 2013-12-23
    Sponsor Name:Biofrontera Bioscience GmbH
    Full Title: A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) in comparison to Metvix® in the treatment of non-aggressive basal cell carcin...
    Medical condition: Basal cell carcinoma (BCC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Dec 08 01:31:10 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA